Compile Data Set for Download or QSAR
Report error Found 214 Enz. Inhib. hit(s) with all data for entry = 11303
TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605617(US11673893, Example 86)
Affinity DataIC50: 0.406nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605531(US11673893, Example 9 | (1S,3R)-N-(5-chloro-4-(7-f...)
Affinity DataIC50: 0.416nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605532(US11673893, Example 10 | (1S,3R)-N-(5-chloro-4-(7-...)
Affinity DataIC50: 0.455nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605523(US11673893, Example 2 | (1S,3R)-N-[5-chloro-4-(7-f...)
Affinity DataIC50: 0.477nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605596(US11673893, Example 65)
Affinity DataIC50: 0.480nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605534(US11673893, Example 12 | (1S,3R)-N-(5-chloro-4-(7-...)
Affinity DataIC50: 0.489nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605533(US11673893, Example 11 | (1S,3R)-N-(5-chloro-4-(7-...)
Affinity DataIC50: 0.498nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605526(US11673893, Example 4 | (1S,3R)-N-(5-chloro-4-(7-f...)
Affinity DataIC50: 0.528nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605551(US11673893, Example 24 | (1S,3R)-3-acetamido-N-(4-...)
Affinity DataIC50: 0.539nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605549(US11673893, Example 22 | (1S,3R)-3-acetamido-N-(4-...)
Affinity DataIC50: 0.694nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605525(US11673893, Example 3 | (1S,3R)-N-(5-chloro-4-(7-f...)
Affinity DataIC50: 0.699nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605573(US11673893, Example 45)
Affinity DataIC50: 0.743nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605529(US11673893, Example 7 | N-[(1R,3S)-3-[[5-chloro-4-...)
Affinity DataIC50: 0.760nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605606(US11673893, Example 76-1)
Affinity DataIC50: 0.780nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605528(US11673893, Example 6 | (1S,3R)-N-[5-chloro-4-(7-f...)
Affinity DataIC50: 0.794nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605581(US11673893, Example 53)
Affinity DataIC50: 0.820nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605618(US11673893, Example 87)
Affinity DataIC50: 0.837nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605604(US11673893, Example 74)
Affinity DataIC50: 0.938nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605592(US11673893, Example 62)
Affinity DataIC50: 0.961nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605571(US11673893, Example 43)
Affinity DataIC50: 0.979nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605530(US11673893, Example 8 | N-((1R,3S)-3-((5-chloro-4-...)
Affinity DataIC50: 0.980nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605572(US11673893, Example 44)
Affinity DataIC50: 0.984nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605558(US11673893, Example 30)
Affinity DataIC50: 1.01nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605563(US11673893, Example 35)
Affinity DataIC50: 1.04nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605527(US11673893, Example 5 | (1S,3R)-N-(5-chloro-4-(7-f...)
Affinity DataIC50: 1.04nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605611(US11673893, Example 80)
Affinity DataIC50: 1.09nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605559(US11673893, Example 31)
Affinity DataIC50: 1.29nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605564(US11673893, Example 36)
Affinity DataIC50: 1.37nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605605(US11673893, Example 75)
Affinity DataIC50: 1.38nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605574(US11673893, Example 46)
Affinity DataIC50: 1.39nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605591(US11673893, Example 61)
Affinity DataIC50: 1.41nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605615(US11673893, Example 84)
Affinity DataIC50: 1.42nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605557(US11673893, Example 29)
Affinity DataIC50: 1.48nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605580(US11673893, Example 52)
Affinity DataIC50: 1.49nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605585(US11673893, Example 56)
Affinity DataIC50: 1.52nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605613(US11673893, Example 82)
Affinity DataIC50: 1.55nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605561(US11673893, Example 33)
Affinity DataIC50: 1.57nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605522(US11673893, Example 1 | (1S,3R)-3-acetamido-N-[5-c...)
Affinity DataIC50: 1.61nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605597(US11673893, Example 66)
Affinity DataIC50: 1.65nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605597(US11673893, Example 66)
Affinity DataIC50: 1.67nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605562(US11673893, Example 34)
Affinity DataIC50: 1.87nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605588(US11673893, Example 59)
Affinity DataIC50: 1.95nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605608(US11673893, Example 77)
Affinity DataIC50: 1.97nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605586(US11673893, Example 57)
Affinity DataIC50: 2nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605555(US11673893, Example 28)
Affinity DataIC50: 2.23nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605589(US11673893, Example 60)
Affinity DataIC50: 2.27nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605578(US11673893, Example 50)
Affinity DataIC50: 2.30nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605541(US11673893, Example 17 | (1S,3R)-N-(5-chloro-4-(5-...)
Affinity DataIC50: 2.31nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605535(US11673893, Example 13 | (1S,3R)-3-acetamido-N-[5-...)
Affinity DataIC50: 2.31nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

TargetCyclin-T1/Cyclin-dependent kinase 9(Human)
Prelude Therapeutics

US Patent
LigandPNGBDBM605599(US11673893, Example 69)
Affinity DataIC50: 2.43nMAssay Description:The inhibitory activity of compounds was evaluated in vitro using TR-FRET assay with white 384-well low volume microplate (Greiner Bio-One). CDK4/Cyc...More data for this Ligand-Target Pair
In Depth
Date in BDB:
7/16/2023
Entry Details
US Patent

Displayed 1 to 50 (of 214 total ) | Next | Last >>
Jump to: